Jovial Wong

Jovial routinely assists clients in the fields of pharmaceuticals, biotechnology, medical devices, and other health care products. He also advises clients on matters related to the Hatch-Waxman Act, the BPCIA, and other regulatory issues, as well as in the development of strategic plans to successfully obtain FDA approval and commercialize drug and biologic products. Jovial has litigated cases in U.S. district courts, in the U.S. Court of Appeals for the Federal Circuit and the District of Columbia Circuit, and in the U.S Supreme Court, as well as before the U.S. Patent Trial and Appeal Board.

Jovial’s patent litigation experience is focused primarily on the pharmaceutical, medical device, and biotechnology industries. This includes cases involving the following drug and biologic products: vancomycin, regadenoson, liraglutide, pegfilgrastim, obeticholic acid, sitagliptin, rifaximin, eluxadoline, buprenorphine/naloxone, sugammadex, ivacaftor, rituximab, lurasidone, apremilast, canagliflozin, dolutegravir, dimethyl fumarate, efinaconazole, empagliflozin, abiraterone, phentermine/topiramate, minocycline, palonosetron, colchicine, doripenem, zoledronic acid, daptomycin, clopidogrel, atomoxetine, docetaxel, and oxaliplatin. Jovial has also handled medical device cases involving artificial hip replacement systems, epinephrine and insulin injector devices, and spinal implants, as well as biotechnology cases involving glyphosate-resistant crops and the production of phytases for use in cereal foods and feeds.

Jovial also co-chairs the Winston Asian Leadership Initiative at the firm and is a member of the Opportunity & Inclusion Committee.